First-in-Class Therapy

 

Elthera AG is developing antibodies against the novel target L1CAM, an adhesion molecule whose expression is strongly correlated with an aggressive tumor phenotype and poor prognosis in various types of cancer. Inhibition of L1CAM targets many mechanisms of tumor progression such as resistance to chemotherapy, escape from immunological control, formation of new blood vessels, tumor growth and metastases formation. The therapy will be developed using the established approach of humanized antibodies, thus allowing fast development into clinical studies without the potential risk of other formats. By combining targeted anti-L1CAM therapy with companion diagnostics, Elthera AG is aiming at providing new personalized treatment options for patients with the most aggressive malignancies.